Personal

Ahmad S

Final Opportunity to Join BioticsAI Before Valuation Increase

Sufra Health x BioticsAI Investor Spotlight and FDA Update Session

BioticsAI, the recent winner of TechCrunch Disrupt and a category leader in AI-powered prenatal care, has achieved a pivotal regulatory milestone. The FDA has formally accepted their clinical study data, with only minor items remaining ahead of clearance.

This milestone removes the final gating item before the company’s next valuation step. With momentum accelerating, BioticsAI is now closing its current round and transitioning to the next pricing tier.

The current $30M valuation cap closes Tuesday, November 4.

Following this date, new capital will enter at a $60M valuation as the team moves toward its next round.

This session provides a final opportunity for qualified angels and healthcare operators in the Sufra ecosystem to meet the founding team, review the latest regulatory progress, and understand the investment thesis before terms change.

Sufra health X BioticsAI